NCT05880563View on ClinicalTrials.gov

Investigation of Cannabinoid 2-receptor Expression in the Brain and Spine of ALS-patients Compared to Healthy Controls With PET (18F-RoSMALS)

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

[18F]-RoSMA-18-d6

\[18F\]-RoSMA-18-d6 will be administered intravenously by a bolus injection followed by a subsequent PET/CT-scan of the brain and the spine

Trial Locations (1)

9000

Muskelzentrum/ALS-Clinic, Kantonsspital St. Gallen, Sankt Gallen

All Listed Sponsors
collaborator

ETH Zurich

OTHER

collaborator

Insel Gruppe AG, University Hospital Bern

OTHER

lead

Markus Weber

OTHER

NCT05880563 - Investigation of Cannabinoid 2-receptor Expression in the Brain and Spine of ALS-patients Compared to Healthy Controls With PET (18F-RoSMALS) | Biotech Hunter | Biotech Hunter